You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company's original lawsuit, filed last March, accused Natera of infringing on two patents it holds in conjunction with Stanford University.
The company said testing revenues rose 54 percent during the quarter, and that it provided 63 percent more patient results year over year.
CareDx first sued Natera in April 2019, accusing the company of trying to mislead patients and clinicians about the superiority of its Prospera transplant test.
News items for the in vitro diagnostics industry for the week of Feb. 10, 2020.
Of the 28 companies in the index, 16 companies' share prices increased while the share values of 12 declined month over month.
News items for the in vitro diagnostics industry for the week of Jan. 27, 2020.
The patent, which was awarded Jan. 7, covers cell-free DNA-based diagnostic methods, including those used in transplant medicine.
The company said preliminary revenues for full-year 2019 are expected to increase 66 percent year over year.
The AlloSeq cfDNA kit is used to quantify the level of donor-derived cell-free DNA in transplant recipients in order to measure graft health.
The magistrate did recommend that the court dismiss two counts made against Natera with respect to trademark disparagement and unfair trade practices.
